Ind-Swift Laboratories allots 70 lakh promoter-group warrants at ₹196 each

In the second quarter we are expecting a major push from Arrotex on that Macrogol new molecule which we launched.

And in third and fourth quarter we see a lot of progress coming from Ibuprofen and Clarithromycin granules.

Looking ahead, on the domestic side we are focused on expanding our ethical footprint into peninsular India and into high-growth chronic therapeutic categories, targeting 15-20% CAGR growth in this business.

We expect FY27 to witness revenue growth of more than 50%.

FY30 is very long way to go, but yes, we would look for a revenue of minimum ₹1500 crores of a revenue and maybe a net profit of approx ₹200 plus.

We may revise this. We don't want to overproject and want to say that we'll do this one year in advance. But by the end of the financial year, we'll revisit all these numbers.